Perimenopause shouldn't be a diagnosis you have to fight for.
Millions of women spend years symptomatic before anyone connects the dots. We're building the clinical evidence and care pathways to close that gap — starting with a validated biomarker.
Right now, there's no reliable, objective test for perimenopause. Women are told to "wait it out," misdiagnosed, or bounced between specialists for years before getting answers. The Perimenopause Society is changing that.
We're running a clinical study to validate sdLDL-C as a standalone diagnostic biomarker for perimenopause — building on peer-reviewed research linking it to perimenopausal status.
This work is early, concrete, and fundable — and it's built by people who've lived the gap we're trying to close.
Every dollar goes toward research and care infrastructure that doesn't exist yet — and needs to.
$25
Helps cover participant recruitment materials for the biomarker study
$100
Supports one participant's full study visit and lab work
$500
Contributes to a full Menopause Rating Scale + biomarker data pair
$2500
Founding Partner level; includes a personal update from our founder on study progress
Research References
The Perimenopause Society's biomarker research builds on peer-reviewed findings (He et al., Frontiers in Endocrinology, 2025) and is developed alongside an OB/GYN and clinical research partners.